The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus
disease 2019 (COVID-19) has killed hundreds of thousands of humans in a global …

Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

Abstract During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for
ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according …

The view of the multiple sclerosis (MS) therapeutic landscape became clouded by the onset
of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previous …

Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …

We read the letter by Piquet, Corboy, and Vollmer related to our recent paper on the humoral
immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated …

Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …

Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in
desperate need of a protection against SARS-CoV-2 infection. Methods In this study …

Background The COVID-19 epidemic raises important questions about the efficacy of
vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been …

Most of our patients (13/16) were treated before December 2021 using a combination of
monoclonal antibodies (casivirimab+ imdevimab and bamlanivimab+ etesevimab) because …